SCHEMBL2019824

SCHEMBL2019824

O=Cc1ccc(OCc2cccc(Br)c2)cc1

nearest known ligand 0.76

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MAOB P27338 13/20 0.76
MAOA P21397 7/20 0.76
ALDH1A1 P00352 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
RAB9A P51151 1/20 0.61
PARP15 Q460N3 2/20 0.61
PARP10 Q53GL7 2/20 0.61
PARP14 Q460N5 1/20 0.61
FFAR1 O14842 1/20 0.58
FFAR4 Q5NUL3 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30398583 1.00 MAOB (0.76) MAOBMAOAALDH1A1SMN1; SMN2RAB9A
SCHEMBL8545870 0.89 RAB9A (0.71) MAOBMAOAALDH1A1SMN1; SMN2RAB9A
SCHEMBL12578130 0.85 MAOB (0.56) MAOBMAOAALDH1A1SMN1; SMN2RAB9A
SCHEMBL12578135 0.84 MAOB (0.55) MAOBMAOAALDH1A1SMN1; SMN2RAB9A
SCHEMBL9454264 0.83 MAOB (0.89) MAOBMAOAALDH1A1SMN1; SMN2RAB9A
SCHEMBL27983208 0.83 RAB9A (0.63) MAOBMAOAALDH1A1SMN1; SMN2RAB9A
SCHEMBL13220846 0.81 MAOB (0.76) MAOBMAOARAB9AFFAR1
SCHEMBL3423658 0.81 MAOB (0.65) MAOBMAOARAB9A
SCHEMBL1164139 0.81 MAOB (0.74) MAOBMAOAALDH1A1RAB9AFFAR1
SCHEMBL29464145 0.81 MAOB (0.76) MAOBMAOARAB9APARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112010818-B Morpholinamide derivatives and uses thereof 广东东阳光药业股份有限公司 2024-01-16 CN disclosed
EP-3762364-B1 PYRROLIDINEAMIDE DERIVATIVES AND USES THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2023-08-23 EP disclosed
CN-110240557-B Pyrrolidine amide derivatives and use thereof 广东东阳光药业有限公司 2023-05-09 CN disclosed
US-11225460-B2 Pyrrolidineamide derivatives and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2022-01-18 US disclosed
CN-108912029-B Nitrogen-containing heterocyclic amide derivative and use thereof 广东东阳光药业有限公司 2021-10-01 CN disclosed
US-20210053918-A1 PYRROLIDINEAMIDE DERIVATIVES AND USES THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2021-02-25 US disclosed
CN-112010818-A Morpholine amide derivative and application thereof 广东东阳光药业有限公司 2020-12-01 CN disclosed
CN-110240557-A Pyrrolidine derivative and application thereof 广东东阳光药业有限公司 2019-09-17 CN disclosed
CN-108912029-A Nitrogen-containing heterocycle amide derivatives and application thereof 广东东阳光药业有限公司 2018-11-30 CN disclosed
US-9884832-B2 Inhibitors targeting drug-resistant influenza A THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2018-02-06 US disclosed
US-7968552-B2 Oxadiazolidinedione compound ASTELLAS PHARMA INC. (JP) 2011-06-28 US disclosed
US-7968552-B2 Oxadiazolidinedione compound ASTELLAS PHARMA INC. (JP) 2011-06-28 US disclosed
US-20100216762-A1 Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof ABBOTT LABORATORIES (US) 2010-08-26 US disclosed
US-20100216762-A1 Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof ABBOTT LABORATORIES (US) 2010-08-26 US disclosed
WO-2010093704-A1 AGONISTS AND ANTAGONISTS OF THE S1P5 RECEPTOR, AND METHODS OF USES THEREOF ABBOTT LABORATORIES (US) 2010-08-19 WO disclosed
US-20090186909-A1 Oxadiazolidinedione Compound ASTELLAS PHARMA INC. (JP) 2009-07-23 US disclosed
US-20090186909-A1 Oxadiazolidinedione Compound ASTELLAS PHARMA INC. (JP) 2009-07-23 US disclosed
US-20090186909-A1 Oxadiazolidinedione Compound ASTELLAS PHARMA INC. (JP) 2009-07-23 US disclosed
EP-2011788-A1 OXADIAZOLIDINEDIONE COMPOUND Astellas Pharma Inc. (JP) 2009-01-07 EP disclosed
EP-2011788-A1 OXADIAZOLIDINEDIONE COMPOUND Astellas Pharma Inc. (JP) 2009-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186909-A1 Oxadiazolidinedione Compound GPR119, GPR39, GPR65 MAOB 3965/4885MAOA 4379/4885ALDH1A1 3249/4885
US-20100216762-A1 Agonists and Antagonists of the S1P5 Receptor, and Methods of Use Thereof S1PR5, LPAR5, S1PR1 MAOB 2578/4885MAOA 1922/4885ALDH1A1 1328/4885
US-11225460-B2 Pyrrolidineamide derivatives and uses thereof MAOB, MAOA, PARK7 MAOB 1/4885MAOA 2/4885ALDH1A1 1191/4885
US-20210053918-A1 PYRROLIDINEAMIDE DERIVATIVES AND USES THEREOF MAOB, MAOA, PARK7 MAOB 1/4885MAOA 2/4885ALDH1A1 1191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.